RedHill Biopharma Secures $1.8M+ Middle East Deal for Talicia®

TL;DR

RHBP inks $1.8M+ Middle East deal for Talicia®, royalties to follow.

AI Summary

RedHill Biopharma Ltd. announced on October 6, 2025, a new Middle East distribution deal for its drug Talicia®. The agreement is valued at over $1.8 million, plus additional sales royalties, with a partner in the Middle East region.

Why It Matters

This deal expands the global reach of RedHill's key drug, Talicia®, potentially increasing revenue and market penetration in a new geographical region.

Risk Assessment

Risk Level: medium — The deal is significant, but the actual financial impact depends on future sales performance and the specifics of the royalty structure.

Key Numbers

• $1.8M+ — Middle East Deal Value (Represents the upfront value of the new distribution agreement for Talicia®.)

Key Players & Entities

• RedHill Biopharma Ltd. (company) — Registrant and seller of Talicia®
• Talicia® (product) — Drug subject to the distribution deal
• $1.8 Million (dollar_amount) — Minimum value of the Middle East deal
• October 2025 (date) — Reporting period for the Form 6-K

FAQ

Key Financial Figures

• $1.8 Million — entitled: "RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal F
• $500,000 — s of the agreement RedHill will receive $500,000 in guaranteed payments, including a $
• $250,000 — 0 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed p
• $1.3 million — e within 18 months, plus a minimum of $1.3 million in near-term potential milestone paymen
• $1.8 million — ast markets in a deal worth potentially $1.8 million plus sales royalty payments. Under the

Filing Documents

• zk2533838.htm (6-K) — 46KB
• image00001.jpg (GRAPHIC) — 657KB
• 0001178913-25-003471.txt ( ) — 951KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: October 6, 2025 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer Press Release RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia The deal aims to accelerate Talicia's entry into new Middle East markets -- Under the terms of the agreement RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months, plus a minimum of $1.3 million in near-term potential milestone payments, as well as tiered royalties up to mid-teens percent on Talicia net sales -- Talicia is the only FDA-approved all-in-one, low-dose rifabutin-based therapy to address H. pylori antibiotic resistance. It is the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy 1 and is first-line treatment listed in the American College of Gastroenterology (ACG) Clinical Guidelines 2 -- H. pylori, a bacterial infection affecting >50% of the world's adult population 3 , and up to almost 80% in parts of the Middle East 4 , is a WHO-designated Group 1 carcinogen and key risk factor for gastric cancer 5 , which causes around 800,000 deaths globally 6 -- Talicia is patent protected through 2042 and received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation RALEIGH, N.C., October 6, 2025 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the licensing of Talicia for new Middle East markets in a deal worth potentially $1.8 million plus sales royalty payments. Under the terms of the agreement, RedHill will receive $500,000 in guaranteed payments, includi

Forward Looking Statements

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words, and include, among others, statements regarding the potential impact of Talicia. Forward-looking statements are based on certain assumptions and are forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions; the Company's ability to maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applicatio

View Full Filing

View this 6-K filing on SEC EDGAR